Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical innovator, Covalon Technologies (TSXV:COV), has unveiled a new antimicrobial technology designed to kill the COVID-19 virus
  • CovaGuard’s formula can kill viruses on contact, and will also provide surface protection for up to four days
  • The product could eventually lead to manufacturing of hand sanitisers, surgical scrubs, antiseptics, sanitising sprays, and more
  • Covalon has filed for a patent on the CovaGuard technology
  • Covalon Technologies (COV) is currently steady at C$1.28 per share, with a market cap of $33.05 million

Medical innovator, Covalon Technologies (TSXV:COV), has unveiled a new antimicrobial technology designed to kill the COVID-19 virus.

The company has formulated CovaGuard to kill a range of viruses, bacteria, and pathogens on contact. Based on previous testing, the technology will also offer sustained surface protection for up to four days.

Like most sanitisers, CovaGuard’s manufacturing process starts with a base of highly-concentrated alcohol. However, alcohol has a very low evaporative threshold, resulting in only a short period of surface protection.

To combat this, Covalon has integrated a variety of other ingredients designed to trap, deactivate, and kill viruses.

Brian Pedlar, CEO of Covalon Technologies, noted that the development arose from a dedicated COVID-19 task force.

“Our mission was to create new technology that could help reduce the spread of COVID-19, and protect healthcare workers, first responders, patients, and the general public,” he said.

Covalon says that the company has filed a patent for CovaGuard. A range of regulatory-compliant products that may be able to use the technology have already been identified.

Modified versions of the product could also eventually lead to hand sanitisers, surgical scrubs, first-aid antiseptics and medical equipment cleaners.

Dr. Val DiTizio, Covalon’s Chief Scientific Officer, also commented on the new development.

“The protective barrier that CovaGuard creates on the skin mimics the natural lipid barriers that are found on skin.

“The difference is that the CovaGuard barrier contains antimicrobials that actively kill pathogens, including enveloped viruses like COVID-19,” he said.

Covalon is currently exploring partnership options with a number of large medical companies and manufacturers. In the meantime, the company plans to begin manufacturing a CovaGuard Hand Sanitizer and a CovaGuard Medical Mask Sanitizer Spray.

Covalon Technologies (COV) is currently steady at C$1.28 per share, as of 11:21am EST.

More From The Market Herald
Knight Therapeutics - President and CEO, Samira Sakhia.

" Knight Therapeutics (TSX:GUD) to relaunch AKYNZEO in Canada

Knight (GUD) has assumed full commercial activities for oral AKYNZEO in Canada.

" Salona Global (TSXV:SGMD) announces US$10 million private placement of debenture units

Salona Global Medical Device Corp. (SGMD) has announced its intention to embark on a private placement for gross proceeds of up to US$10,000,000.

" Therma Bright (TSXV:THRM) invests in inhalable statin technology

Therma Bright (THRM) has invested in inhalable statin treatments for respiratory conditions.

" Revive Therapeutics (CSE:RVV) announces $5M private placement

Revive Therapeutics (RVV) has announced a private placement for gross proceeds of between $3 million and $5 million.